Jung+ Launches Holistic Longevity Program, Offering an Accessible, One-Stop-Shop for the Cutting Edge of Longevity Science

Jung+, a science-backed, human-forward company rewriting the standard approach to longevity care, announces its launch after completing a successful private beta phase with a 10,000-strong community.

Founded by Simon Sakhai, a University of Oxford alum and former President of the Oxford Society of Ageing and Longevity, Jung+ brought together high-profile global longevity experts, scientists, and doctors. With five years of research and development, Jung launched its Total Longevity System™, a seamless system that allows users to create a holistic longevity regimen tailored to their lifestyle and goals. The products have been engineered with ingredients backed by science to target the drivers of aging and optimize human performance.

While high-end longevity clinics offer annual programs costing $100,000+, Jung+ democratizes longevity solutions through its three-step system, which offers the majority of results at a fraction of the cost. Jung+ is currently available DTC and will soon be available to functional doctors and preventative clinicians as a tool for patients.

Customers start their regimen with a master longevity formula, the Longevity Foundation, a two-part around-the-clock supplement protocol that addresses all 12 drivers of aging. With ingredients administered at times that are naturally tailored to the body’s rhythm, the Longevity Foundation’s approach is designed to coincide with biological mechanisms for maximum impact.

Longevity cannot be tackled with a one-size-fits-all approach. To personalize the program, customers select from longevity boosters: individual supplements & coaching protocols that target longevity goals. Boosters include:

  • Fasting Tonic: Intermittent fasting and calorie restriction are among the most powerful longevity hacks. This precision drink mix is engineered to ease and enhance the intermittent fasting experience, promoting feelings of fullness, replenishing important nutrients lost while fasting, and safeguarding against muscle loss.
  • Advanced Sleep Repair: Known as nature’s longevity miracle, sleep optimizes almost every biological and cognitive process, making quality sleep an essential part of the longevity lifestyle. Advance Sleep Repair enhances sleep’s regenerative mechanisms, leading to restful sleep that balances natural melatonin and neurotransmitter levels, optimizes nocturnal DNA and tissue repair and more.
  • Cellular Skin Renewal: Superior to topical creams and serums, this is the only skin supplement to leverage cutting-edge longevity science to combat biological skin aging from the inside out. The formula addresses every hallmark of skin aging, such as depleted NAD+ levels, building senescent cells, decline in fibroblasts, and symptoms like wrinkles, elasticity and skin tone/texture.
  • Glucose Blocker: This supplement protects against one of the most damaging, age-accelerating lifestyle issues: an excess of carbs and sugar in a diet. By regulating post-meal glucose levels, it provides steady energy, aids in anti-aging by switching on longevity mechanisms, supports healthy weight management, targets inflammation, and tempers the formation of AGEs which drive wrinkles.

Recognizing that science is constantly changing, Jung+ continuously reviews formulations based on the latest scientific research, ensuring customers benefit from the most up-to-date advancements without the need to navigate the complex landscape of longevity science alone.

“At Jung+, we’re on a crusade to liberate human longevity for all, translating the latest scientific advancements in aging research into products and technologies that can slow aging and extend healthy lifespan,” said Simon Sakhai, CEO & Founder of Jung+. “With longevity gaining popularity, it’s imperative that experts ensure that living a longer life is accessible for everyone.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version